[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.248.25. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
Health Policy
April 23/30, 2019

Novel Therapies for an Aging Population: Grappling With Price, Value, and Affordability

Author Affiliations
  • 1Meyers Primary Care Institute, a joint endeavor of University of Massachusetts Medical School, Fallon Health, and Reliant Medical Group, Worcester
  • 2Division of Geriatric Medicine, University of Massachusetts Medical School, Worcester
  • 3Institute for Clinical & Economic Review, Boston, Massachusetts
JAMA. 2019;321(16):1567-1568. doi:10.1001/jama.2019.2633

The US health care sector is beginning to experience the full effect of the aging “baby boomer” population, 76 million of whom were born between 1946 and 1964, with nearly half eligible for Medicare in the coming year. In 2018, Medicare costs amounted to 14% of total federal spending, and by 2028, are projected to increase to 18%.1 Growing enrollments, increased use of services, and rising prices for prescription drugs are major drivers of these increasing costs.2

×